Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Single-dose PK Study of Ceftazidime-Avibactam In Hospitalized Children Receiving Systemic Antibiotics for Nosocomial Pneumonia

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04040621
Recruitment Status : Terminated (Following regulatory consultation, the Sponsor has decided to terminate the study and analyze the current dataset. The decision to terminate was solely based on a business decision, not due to safety concerns.)
First Posted : August 1, 2019
Last Update Posted : November 19, 2021
Sponsor:
Collaborator:
AbbVie
Information provided by (Responsible Party):
Pfizer

Brief Summary:
This is a multicenter, multinational, open label single dose pharmacokinetic (PK) study enrolling at least 32 subjects. The study aims to characterize the pharmacokinetics (PK) of a single intravenous dose of CAZ AVI in pediatric subjects aged 3 months to less than 18 years who are receiving systemic antibiotic therapy for suspected or confirmed nosocomial pneumonia, including ventilator associated pneumonia.

Condition or disease Intervention/treatment Phase
Hospitalized Children With Suspected or Confirmed Nosocomial Pneumonia Drug: Ceftazidime-avibactam Phase 1

Detailed Description:
This is a multicenter, multinational, open label single dose pharmacokinetic (PK) study enrolling at least 32 subjects. The study aims to characterize the PK of CAZ AVI and assess its safety and tolerability following a single intravenous (IV) infusion. Subjects will be hospitalized pediatric patients who are receiving systemic antibiotic therapy for suspected or confirmed nosocomial pneumonia (NP), including ventilator associated pneumonia (VAP). The study will consist of a Screening visit (Visit 1, Day 1), during which consent will be obtained and subject eligibility will be confirmed, a Baseline/Treatment visit (Visit 2, Day 1) during which subjects will receive a single IV infusion of CAZ AVI, and then two follow up assessment visits at 24 hours (Visit 3, Day 2) and 48 hours (Visit 4, Day 3). Blood samples for PK analyses (0.5 mL per sample) will be obtained over 22 hours for Cohort 1 (7 samples), over 13 hours for Cohort 2 (6 samples), and over 6 hours for Cohorts 3 and 4 (4 samples). Additionally, for subjects who are undergoing bronchoalveolar lavage (BAL) for clinical purposes and for whom informed consent is obtained specifically for BAL, an epithelial lining fluid (ELF) sample will be collected for estimation of CAZ AVI concentrations.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 4 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Intervention Model Description: Non-randomized, single arm
Masking: None (Open Label)
Primary Purpose: Basic Science
Official Title: A PHASE 1, OPEN-LABEL, SINGLE-DOSE STUDY TO ASSESS THE PHARMACOKINETICS, SAFETY AND TOLERABILITY OF CEFTAZIDIME-AVIBACTAM (CAZ-AVI) IN CHILDREN FROM 3 MONTHS TO LESS THAN 18 YEARS OF AGE WHO ARE HOSPITALIZED AND RECEIVING SYSTEMIC ANTIBIOTIC THERAPY FOR SUSPECTED OR CONFIRMED NOSOCOMIAL PNEUMONIA, INCLUDING VENTILATOR-ASSOCIATED PNEUMONIA
Actual Study Start Date : June 15, 2020
Actual Primary Completion Date : April 9, 2021
Actual Study Completion Date : May 7, 2021


Arm Intervention/treatment
Experimental: Ceftazidime-avibactam
This arm includes 4 cohorts
Drug: Ceftazidime-avibactam
Single intravenous infusion of ceftazidime-avibactam over 2 hours. Dosage will vary depending upon age, weight and renal function.




Primary Outcome Measures :
  1. Area under the plasma concentration curve [ Time Frame: time profile from time 0 to 8 hours ]
    PK parameters of ceftazidime and avibactam for cohorts 1 and 2

  2. Area under the plasma concentration time profile from time 0 to infinity [ Time Frame: Up to 22 hours post infusion for cohort 1, up to 13 hours post infusion for cohort 2 ]
    PK parameters of ceftazidime and avibactam for cohorts 1 and 2

  3. Area under the plasma concentration time profile from time 0 to the last quantifiable concentration [ Time Frame: Up to 22 hours post infusion for cohort 1, up to 13 hours post infusion for cohort 2 ]
    PK parameters of ceftazidime and avibactam for cohorts 1 and 2

  4. Maximum plasma concentration [ Time Frame: Up to 22 hours post infusion for cohort 1, up to 13 hours post infusion for cohort 2 ]
    PK parameters of ceftazidime and avibactam for cohorts 1 and 2

  5. Time of last quantifiable plasma concentration [ Time Frame: Up to 22 hours post infusion for cohort 1, up to 13 hours post infusion for cohort 2 ]
    PK parameters of ceftazidime and avibactam for cohorts 1 and 2

  6. Time for Cmax [ Time Frame: Up to 22 hours post infusion for cohort 1, up to 13 hours post infusion for cohort 2 ]
    PK parameters of ceftazidime and avibactam for cohorts 1 and 2

  7. Terminal elimination half life [ Time Frame: Up to 22 hours post infusion for cohort 1, up to 13 hours post infusion for cohort 2 ]
    PK parameters of ceftazidime and avibactam for cohorts 1 and 2

  8. Clearance [ Time Frame: Up to 22 hours post infusion for cohort 1, up to 13 hours post infusion for cohort 2 ]
    PK parameters of ceftazidime and avibactam for cohorts 1 and 2

  9. Volume of distribution at steady state [ Time Frame: Up to 22 hours post infusion for cohort 1, up to 13 hours post infusion for cohort 2 ]
    PK parameters of ceftazidime and avibactam for cohorts 1 and 2

  10. Volume of distribution during terminal phase [ Time Frame: Up to 22 hours post infusion for cohort 1, up to 13 hours post infusion for cohort 2 ]
    PK parameters of ceftazidime and avibactam for cohorts 1 and 2

  11. Plasma concentration will be summarized using descriptive statistics, eg, number, mean, SD, minimum, median, maximum, geometric mean, and coefficient of variation. [ Time Frame: Up to 22 hours post infusion for cohort 1, up to 13 hours post infusion for cohort 2, and up to up to 6 hours post infusion for cohorts 3 and 4 ]
    For each cohort 1-4


Secondary Outcome Measures :
  1. Number of subjects with adverse Events (AE) and Serious Adverse Events (SAEs) [ Time Frame: Screening through 28-35 days post infusion ]
    Adverse events will be summarized by preferred term and system organ class using the MedDRA vocabulary (Version 14.0 or higher) by cohort.

  2. Number of subjects with clinically significant abnormal laboratory results [ Time Frame: Screening through 28-35 days post infusion ]
  3. Number of subjects with clinically significant abnormal vital signs [ Time Frame: Screening through 28-35 days post infusion ]
  4. Number of deaths reported for study subjects [ Time Frame: Screening through 28-35 days post infusion ]
  5. Number of subjects discontinued due to AEs [ Time Frame: Screening through 28-35 days post-infusion ]
  6. Number of subjects with abnormal findings from physical examinations performed [ Time Frame: Screening visit and 48 hour assessment ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   3 Months to 17 Years   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

Subjects must meet all of the following inclusion criteria to be eligible for enrollment into the study:

  1. Evidence of a personally signed and dated informed consent document indicating that the subject's parent(s), legal guardian, or legally acceptable representative has been informed of all pertinent aspects of the study. As appropriate per local requirements informed assent of subjects must also be documented.
  2. Willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures.
  3. Male or female children age ≥3 months to <18 years at Screening:

    1. Cohort 1: age 12 years to <18 years;
    2. Cohort 2: age 6 years to <12 years;
    3. Cohort 3: age 2 years to <6 years;
    4. Cohort 4: age 3 months to <2 years (must be born ≥37 weeks gestational age).
  4. Hospitalized, receiving systemic antibiotic therapy for the treatment of a suspected or confirmed HAP or VAP meeting the following criteria, and expected to require hospitalization until after the follow up evaluations are completed on Day 3 (48 hours after the end of infusion):

    1. Onset of symptoms ≥48 hours after admission or <7 days after discharge from an inpatient acute or chronic care facility;
    2. New or worsening infiltrate on chest X ray;
    3. At least 1 of the following systemic signs prior to the initiation of treatment for Nosocomial Pneumonia:

    i. Fever (temperature >38°C) or hypothermia (rectal/core temperature <35°C); ii. White blood cell (WBC) count >10,000 cells/mm3, or WBC count <4,500 cells/mm3, or >15% band forms.

    d. At least 2 of the following respiratory signs or symptoms: i. A new onset of cough (or worsening of cough). ii. Production of purulent sputum or endotracheal secretions. iii. Auscultatory findings consistent with pneumonia/pulmonary consolidation (eg, rales, rhonchi, bronchial breath sounds, dullness to percussion, egophony).

    iv. Dyspnea, tachypnea or hypoxemia (O2 saturation <90% or PaO2 <60 mmHg while breathing room air).

    v. A need for mechanical ventilation or, for already ventilated subjects, acute changes made in the ventilator support system to enhance oxygenation, as determined by, for example arterial blood gas or worsening PaO2/FiO2.

  5. Likely to survive the current illness or hospitalization.
  6. Sufficient IV access (peripheral or central) to receive study drug and dedicated access for PK sampling.

Exclusion Criteria:

Subjects with any of the following characteristics/conditions will not be included in the study:

  1. Investigator site staff members directly involved in the conduct of the study and their family members, site staff members otherwise supervised by the Investigator, or subjects who are Pfizer employees, including their family members, directly involved in the conduct of the study.
  2. Participation in other studies involving investigational drug(s) within 30 days prior to study entry and/or during study participation.
  3. Other acute or chronic medical or psychiatric condition including recent (within the past year) or active suicidal ideation or behavior or laboratory abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the Investigator, would make the subject inappropriate for entry into this study.
  4. Past or current history of epilepsy or seizure disorder (excluding childhood febrile seizures.
  5. Severe renal impairment defined as creatinine clearance (CrCL) ≤30 mL/min/1.73 m2 calculated using the child's measured height (length) and serum creatinine with the Bedside Schwartz equation (Schwartz, Munoz, et al., 2009):3 CrCL (mL/min/1.73 m2) =
  6. Documented history of any hypersensitivity or allergic reaction to any β lactam antibiotic.
  7. Pregnant female subjects; breastfeeding female subjects; fertile male subjects and female subjects of childbearing potential who are unwilling or unable to use a highly effective method of contraception as outlined in this protocol for the duration of the study and for at least 28 days after the last dose of CAZ AVI.
  8. Acute hepatitis in the prior 6 months, a prior history of cirrhosis, acute hepatic failure, or acute decompensation of chronic hepatic failure; and/or any of the following blood test results, for any individual, when assessed for eligibility:

    1. Bilirubin >3 × upper limit of normal (ULN), unless isolated hyperbilirubinemia is directly related to the acute infection or due to known Gilbert's disease;
    2. ALT or AST >3 × ULN values used by the laboratory performing the test. Subjects with values >3 × ULN and <5 × ULN are eligible if this value is acute and directly related to the infectious process being treated. This must be documented;
    3. ALP >3 × ULN. Subjects with values >3 × ULN and <5 × ULN are eligible if this value is acute and directly related to the infectious process being treated. This must be documented.
  9. Any condition (eg, septic shock, burns, cystic fibrosis, acute hemodynamic instability, including those conditions not responding to pressor support) that would make the patient, in the opinion of the Investigator, unsuitable for the study (eg, would place a patient at risk; compromise the quality of the data; or interfere with the absorption, distribution, metabolism, or excretion of CAZ AVI).
  10. Receipt of a blood or blood component or scheduled for transfusion within the PK sampling period (eg, red blood cells, fresh frozen plasma, platelets) transfusion during the 24 hour period before enrollment.
  11. Body mass index (BMI) below the 5th percentile or above the 95th percentile for height, age, and weight except for children <2 years of age as BMI is not considered a screening tool for healthy weight in children under 2 years of age.
  12. Treatment with ceftazidime within 12 hours of CAZ AVI administration or treatment with ceftazidime within 24 hours of CAZ AVI administration in subjects with renal impairment (CrCL ≤50 mL/min/1.73 m2).
  13. Treatment with potent inhibitors of OAT1 and/or OAT3 (eg, probenecid, p aminohippuric acid (PAH), or teriflunomide).

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04040621


Locations
Layout table for location information
China, Jiangsu
Wuxi Children's Hospital
Wuxi, Jiangsu, China, 214023
China, Sichuan
Chengdu Women's and Children's Central Hospital
Chengdu, Sichuan, China, 610091
Taiwan
Taipei Municipal Wanfang Hospital
Taipei, Taiwan, 116
Chang Gung Memorial Hospital-Linkou
Taoyuan City, Taiwan, 333
Sponsors and Collaborators
Pfizer
AbbVie
Investigators
Layout table for investigator information
Study Director: Pfizer CT.gov Call Center Pfizer
Additional Information:
Layout table for additonal information
Responsible Party: Pfizer
ClinicalTrials.gov Identifier: NCT04040621    
Other Study ID Numbers: C3591025
2018-002841-12 ( EudraCT Number )
EMBA ( Other Identifier: Alias Study Number )
First Posted: August 1, 2019    Key Record Dates
Last Update Posted: November 19, 2021
Last Verified: November 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Plan Description: Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Pfizer:
nosocomial pneumonia, NP
Additional relevant MeSH terms:
Layout table for MeSH terms
Pneumonia
Healthcare-Associated Pneumonia
Respiratory Tract Infections
Infections
Lung Diseases
Respiratory Tract Diseases
Cross Infection
Iatrogenic Disease
Disease Attributes
Pathologic Processes
Ceftazidime
Avibactam
Avibactam, ceftazidime drug combination
Anti-Bacterial Agents
Anti-Infective Agents
beta-Lactamase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action